Last updated: February 20, 2026
What Are the Scope and Claims of EP1613296?
EP1613296, filed by Bristol-Myers Squibb on October 2, 2002, and granted on April 14, 2010, covers specific chemical compounds and their use as pharmaceuticals. The patent claims encompass a class of heteroaryl-substituted compounds with specified structural features designed for therapeutic activity, particularly as kinase inhibitors.
Key Elements of the Claims
-
Compound Structure: The patent claims define a heteroaryl group attached to a core scaffold, with substitution patterns including various heteroatoms (e.g., nitrogen, oxygen, sulfur), substituents such as alkyl, aryl, or halogens.
-
Pharmacological Use: The claims specify the use of these compounds as inhibitors of particular kinases, notably antibodies or small molecules targeting cancer-related pathways such as BCR-ABL, RET, or other receptor tyrosine kinases.
-
Method of Use: Claims include methods of treating diseases, especially cancer, associated with abnormal kinase activity by administering the claimed compounds.
-
Prodrug and Variants: The patent extends its scope to prodrugs, derivatives, and salts of the claimed compounds, broadening the potential coverage.
Claim Breadth and Limitations
The claims are broad, covering multiple compound variants within defined chemical classes. They focus on structural features critical for kinase inhibition efficacy, with dependent claims narrowing the scope to specific substitutions or configurations. The breadth encompasses compounds with potential applications in multiple oncological indications, providing extensive patent protection.
What Does the Patent Landscape Look Like for EP1613296?
Patent Family and Related Rights
-
Priority and Family Members: The patent family includes applications in the US (US7221324), Japan (JP4752382), and China (CN1783494), with priority back to October 2, 2001. These ensure worldwide protection.
-
Subsequent Filings: Bristol-Myers Squibb filed continuation and divisional applications, expanding the scope related to kinase inhibitors and specific chemical classes.
Competitor Filings and Overlaps
-
Similar Patents: Several patents filed by competitors cover kinase inhibitors structurally similar to those claimed, notably in the oncology space. These include filings by companies like Novartis, AstraZeneca, and Pfizer, focusing on heteroaryl compounds targeting kinases such as VEGFR and EGFR.
-
Patent Thickets: The landscape features densely layered patents covering compound structures, methods of synthesis, and therapeutic uses. This creates "patent thickets" complicating freedom-to-operate (FTO).
Litigation and Patent Challenges
-
Legal Status: EP1613296 remains in force, with no documented litigations or oppositions against it as of the latest updates.
-
Potential for Non-Patentability Challenges: Given the broad structural scope, challenges based on novelty or inventive step could arise if prior art reveals similar heteroaryl kinase inhibitors.
Patent Term and Expiry
- Expiration Date: The patent is expected to expire around 2022–2023, considering the standard 20-year term plus any adjustments for patent term extensions or supplementary protections.
What Are the Strategic Implications?
-
The patent provides Bristol-Myers Squibb with exclusivity over a broad class of kinase inhibitors, covering multiple therapeutic indications.
-
The extensive patent family limits competitors' ability to develop similar compounds without infringement, especially in markets where these patents are enforced.
-
The patent landscape around kinase inhibitors is crowded, requiring careful strategy when pursuing FTO, licensing, or developing biosimilars.
Key Takeaways
- EP1613296 claims a broad class of heteroaryl compounds used as kinase inhibitors for cancer therapy.
- The claims incorporate structural features and methods of use that cover multiple therapeutics in oncology.
- The patent family extends protections globally, with filings in key jurisdictions, creating a substantial barrier for competitors.
- The patent’s expiration around 2022–2023 opens opportunities for generic or biosimilar development, pending landscape clearance.
- The crowded patent environment around kinase inhibitors necessitates detailed freedom-to-operate analysis.
FAQs
Q1: What is the primary therapeutic application of the compounds claimed in EP1613296?
A1: The compounds are designed as kinase inhibitors primarily targeting cancer-related pathways, such as BCR-ABL and RET, for treating various cancers.
Q2: How broad are the claims in EP1613296?
A2: The claims cover multiple heteroaryl compounds with specific structural features and their use in kinase inhibition, encompassing derivatives, salts, and prodrugs.
Q3: Are there known patent challenges or litigations involving EP1613296?
A3: No publicly documented challenges or litigations have impacted the patent to date.
Q4: When does EP1613296 expire, and what does this imply for development?
A4: Expiry is expected around 2022–2023, after which generic development may proceed, subject to the patent landscape.
Q5: How competitive is the patent landscape for kinase inhibitors similar to those in EP1613296?
A5: Highly competitive, with multiple patents and filings from various pharmaceutical companies creating layers of protection and competition.
References
- European Patent Office. (2010). Patent EP1613296.
- Bristol-Myers Squibb. (2002). Priority application.
- Patent family filings: US7221324, JP4752382, CN1783494.
